1. Home
  2. BPMC vs BIO Comparison

BPMC vs BIO Comparison

Compare BPMC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPMC
  • BIO
  • Stock Information
  • Founded
  • BPMC 2008
  • BIO 1952
  • Country
  • BPMC United States
  • BIO United States
  • Employees
  • BPMC N/A
  • BIO N/A
  • Industry
  • BPMC Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • BPMC Health Care
  • BIO Industrials
  • Exchange
  • BPMC Nasdaq
  • BIO Nasdaq
  • Market Cap
  • BPMC 5.8B
  • BIO 6.2B
  • IPO Year
  • BPMC 2015
  • BIO N/A
  • Fundamental
  • Price
  • BPMC $101.35
  • BIO $226.40
  • Analyst Decision
  • BPMC Buy
  • BIO Strong Buy
  • Analyst Count
  • BPMC 18
  • BIO 4
  • Target Price
  • BPMC $125.88
  • BIO $330.50
  • AVG Volume (30 Days)
  • BPMC 789.4K
  • BIO 374.2K
  • Earning Date
  • BPMC 05-01-2025
  • BIO 07-31-2025
  • Dividend Yield
  • BPMC N/A
  • BIO N/A
  • EPS Growth
  • BPMC N/A
  • BIO N/A
  • EPS
  • BPMC N/A
  • BIO N/A
  • Revenue
  • BPMC $562,121,000.00
  • BIO $2,541,100,000.00
  • Revenue This Year
  • BPMC $44.49
  • BIO N/A
  • Revenue Next Year
  • BPMC $33.04
  • BIO $3.69
  • P/E Ratio
  • BPMC N/A
  • BIO N/A
  • Revenue Growth
  • BPMC 99.19
  • BIO N/A
  • 52 Week Low
  • BPMC $73.04
  • BIO $215.38
  • 52 Week High
  • BPMC $121.90
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • BPMC 56.34
  • BIO 41.49
  • Support Level
  • BPMC $94.38
  • BIO $220.31
  • Resistance Level
  • BPMC $102.52
  • BIO $233.28
  • Average True Range (ATR)
  • BPMC 3.77
  • BIO 8.26
  • MACD
  • BPMC -0.38
  • BIO -1.40
  • Stochastic Oscillator
  • BPMC 79.29
  • BIO 16.29

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: